Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Agonist CD40 Antibody CDX-1140, Anti-CD40 Agonistic Monoclonal Antibody CDX-1140, CDX 1140
Anti-CD40 Agonist Monoclonal Antibody CDX-1140 · 1 trial · 15 indications
Evaluated according to National Cancer Institute Common Terminology Criteria for adverse events (NCI CTCAE) version (v)5.0. Will be summarized by cohort and grade using frequencies and relative frequencies.
Will be summarized by cohort (with or without CDX 1140) using frequencies and relative frequencies, with the ORR estimated using 90% confidence intervals obtained by Jeffrey's prior method. The final analysis will be performed on all n=80 (40 in each cohort) evaluable patients; and if the p-value is less than or equal to 0.10, then the triplet regimen will be considered superior with respect to response.
| Arm | Type | Description |
|---|---|---|
| Arm I (pembrolizumab, bevacizumab) | ACTIVE_COMPARATOR | Patients receive pembrolizumab IV over 30 minutes and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 3 weeks until disease progression or development of unacceptable toxicity. |
| Arm II (pembrolizumab, bevacizumab, CDX-1140) | EXPERIMENTAL | Patients receive pembrolizumab IV over 30 minutes, bevacizumab IV over 30-90 minutes, and CDX-1140 IV over 90 minutes on day 1. Cycles repeat every 3 weeks until disease progression or development of unacceptable toxicity. |
| Name | Type | Description |
|---|---|---|
| Anti-CD40 Agonist Monoclonal Antibody CDX-1140 | BIOLOGICAL | Given IV |
| Bevacizumab | BIOLOGICAL | Given IV |
| Pembrolizumab | BIOLOGICAL | Given IV |
| Quality-of-Life Assessment | OTHER | Ancillary studies |
| Questionnaire Administration | OTHER | Ancillary studies |
Inclusion Criteria: * Age \>= 18 years of age. * Recurrent serous (low grade or high grade), endometrioid, or clear cell recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. * Participant can be either platinum-sensitive or platinum-resistant, no more than 4 prior lines of tr...
CDX-1140 is an investigational monoclonal antibody developed by Celldex Therapeutics, Inc. (ticker CLDX). It is an anti-CD40 agonist antibody being studied in oncology, specifically in a Phase 2 trial for ovarian clear cell adenocarcinoma and related ovarian, fallopian tube, and primary peritoneal cancers. It is not yet approved and remains in clinical development.
CDX-1140 is being studied for the treatment of ovarian clear cell adenocarcinoma and other recurrent ovarian, fallopian tube, and primary peritoneal carcinomas. In the Phase 2 trial, it is given in combination with pembrolizumab and bevacizumab, or with pembrolizumab alone, in patients with recurrent ovarian cancer.
CDX-1140 targets CD40, a receptor on antigen-presenting cells. As an agonist anti-CD40 monoclonal antibody, it is designed to activate CD40 signaling and stimulate immune responses against tumor cells. It is being evaluated in combination with pembrolizumab, a PD-1 inhibitor, and bevacizumab, a VEGF inhibitor.
CDX-1140 is being developed by Celldex Therapeutics, Inc., which trades under the ticker CLDX. Celldex is the sponsor of the Phase 2 clinical trial evaluating the antibody in recurrent ovarian cancer.
CDX-1140 is in Phase 2 clinical development. It is investigational and has not been approved by the FDA. The ongoing Phase 2 study is currently recruiting participants and has an estimated enrollment of 80 patients.
CDX-1140 is being evaluated in the Phase 2 trial NCT05231122, titled "Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer." The trial is recruiting, active controlled, randomized, and enrolling 80 female participants aged 18 years and older in the United States.